Cytokinetics Secures UK Approval and NICE Recommendation for MYQORZO in Hypertrophic Cardiomyopathy — Cytokinetics, Incorporated

Event summary

Cytokinetics' MYQORZO (aficamten) received MHRA marketing authorization in the UK for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
NICE issued positive guidance recommending aficamten for eligible adult patients in England and Wales.
The approval is based on Phase 3 SEQUOIA-HCM trial data showing a statistically significant improvement in peak oxygen uptake.
Aficamten is the first cardiac myosin inhibitor approved for oHCM, targeting a population of ~500,000 Europeans.

The big picture

This marks Cytokinetics' first commercial product launch, validating its cardiac myosin inhibition platform. The dual MHRA and NICE approvals create a clear regulatory pathway for oHCM treatments in the UK market. With approximately half of HCM patients experiencing the obstructive form, this represents a significant unmet need.

What we're watching

Market Access: The pace at which NHS adoption will proceed following the expected availability later this year.
Commercial Strategy: How Cytokinetics positions aficamten against existing treatments like beta-blockers and disopyramide.
Regulatory Expansion: Whether the MHRA/NICE approvals will accelerate filings in other European markets or the US.